Assays for detecting the presence or amount of an anti-drug antibody

Patent metadata

Field	Value
Publication number	US-9759732-B2
Application number	US-201514619422-A
Country	US
Kind code	B2
Filing date	Feb 11, 2015
Priority date	Feb 11, 2014
Publication date	Sep 12, 2017
Grant date	Sep 12, 2017

Abstract

Methods and kits for detecting antibodies (e.g., anti-drug antibodies). Such methods and kits permit the detection of, for example, anti-drug antibodies in human body fluids, such as blood, plasma and serum.

First claim

What is claimed is:

1. A method for determining the presence or absence of an anti-drug antibody (ADA) in a sample, the method comprising:
contacting the sample with an excess amount of drug to which the ADA binds to form drug/ADA complexes;
contacting the drug/ADA complexes with polyethylene glycol (PEG), wherein the concentration of PEG is between about 0.1% and about 10.0%, to form a precipitate comprising drug/ADA complexes;
contacting the precipitate with an acidic solution to dissociate the drug/ADA complexes, thereby forming a solution of dissociated ADAs and dissociated drugs, wherein the acidic solution is at a concentration of between 0.1 M and 0.5 M and causes the solution of dissociated ADAs and dissociated drugs to have a specific acidic pH;
immobilizing the dissociated ADAs in the solution of dissociated ADAs and dissociated drugs on a substrate under conditions where the dissociation of the ADAs and drugs are maintained, wherein the conditions where the dissociation of the ADAs and drugs are maintained is that the solution of dissociated ADAs and dissociated drugs is maintained at the specific acidic pH;
washing the dissociated ADAs immobilized on the substrate to remove unbound drug;
contacting the ADAs immobilized on the substrate with drug labeled with a detectable label; and
detecting the presence or absence of said detectable label, thereby determining, the presence or absence of ADA in the sample.

2. The method of claim 1 , wherein the substrate comprises a porous carbon surface.

3. The method of claim 1 , wherein the substrate comprises a carbon surface, a glass surface, a silica surface, a metal surface, a polymeric material, a surface containing a metallic or chemical coating, a membrane, a bead, a porous polymer matrix, or substrates comprising cellulosic fibers, or any combination thereof.

4. The method of claim 1 , wherein said detectable label comprises a label selected from the group consisting of a radioactive isotope, an enzyme, a fluorescent label, a chemiluminescent label, an electrochemiluminescent label, and a substrate for an enzymatic detection reaction.

5. The method of claim 1 , wherein the drug comprises an antibody or a functional fragment thereof, a nucleic acid, a peptide, a polypeptide, a peptidomimetic, a carbohydrate, a lipid, an organic small molecule compound, an inorganic small molecule compound, or any combination thereof.

6. The method of claim 1 , wherein the drug is a drug modified to exhibit less immunogenicity as compared to the same drug in unmodified form.

7. The method of claim 1 , wherein the PEG comprises at least one PEG selected from the group consisting of PEG1000, PEG1450, PEG3000, PEG6000, PEG8000, PEG10000, PEG14000, PEG15000, PEG20000, PEG250000, PEG30000, PEG35000, and PEG40000.

8. The method of claim 1 , wherein the acid is selected from the group consisting of citric acid, isocitric acid, glutamic acid, acetic acid, lactic acid, formic acid, oxalic acid, uric acid, trifluoroacetic acid, benzene sulfonic acid, aminomethanesulfonic acid, camphor-10-sulfonic acid, chloroacetic acid, bromoacetic acid, iodoacetic acid, propanoic acid, butanoic acid, glyceric acid, succinic acid, malic acid, aspartic acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, boric acid, hydrofluoric acid, hydrobromic acid, and any combination thereof.

9. The method of claim 1 , wherein the sample comprises the drug.

10. The method of claim 1 , wherein the method further comprises immobilizing the drug on the substrate before or after the step of immobilizing the ADA on the substrate.

11. The method of claim 1 , wherein the sample comprises a biological sample, wherein the biological sample comprises material selected from the group consisting of body fluids, mucus secretions, saliva, blood, whole blood, plasma, and serum.

Assignees

• Genzyme Corp

Inventors

• Grabert Ryan
• Richards Susan
• Theobald Valerie
• Xu Yuanxin
• Zoghbi Jad

Classifications

• G01N2430/00

  Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes · CPC title

• G01N33/94 Primary

  involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors} · CPC title

• G01N33/539

  involving precipitating reagent {, e.g. ammonium sulfate} · CPC title

• G01N33/6854

  Immunoglobulins · CPC title

• G01N33/5306

  Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding · CPC title